Alzheimer’s disease is a progressive neurodegenerative disease that begins slowly and worsens over time. Individuals with Alzheimer’s disease experience a reversal of mental health roles, leaving them incapacitated and unable to perform everyday activities. The elderly are the ones that are most often affected by this disease. However, research suggests that people as young as 40 years old may be affected. It is a form of dementia that has no cure and leads to death over time. Donepezil is a well-known Alzheimer’s disease treatment. The United States Food and Drug Administration (FDA) has approved donepezil hydrochloride as the second drug for the treatment of mild to moderate Alzheimer’s disease (AD). It’s a new kind of acetyl cholinesterase (AChE) inhibitor with an N-benzylpiperidine and an indanone moiety that works for longer and more selectively. Donepezil HCl is a piperidine derivative that is chemically distinct from other AChE inhibitors. It is a highly selective inhibitor of the enzyme AChE. Donepezil is much more selective for AChE in the brain than for butyrylcholinesterase (BuChE) in the periphery, according to in vitro and preclinical studies. This chapter discusses various methods for synthesising donepezil, as well as an enhanced, industrially scalable complete synthesis. Physical and pharmacological properties are also included.
Author (s) Details
Associate Professor Dr. Santosh L. Gaonkar
Department of Chemistry, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
View Book :- https://stm.bookpi.org/CPCS-V8/issue/view/43